| pubmed-article:3169114 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3169114 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:3169114 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:3169114 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:3169114 | lifeskim:mentions | umls-concept:C0016384 | lld:lifeskim |
| pubmed-article:3169114 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:3169114 | lifeskim:mentions | umls-concept:C0870883 | lld:lifeskim |
| pubmed-article:3169114 | lifeskim:mentions | umls-concept:C0205164 | lld:lifeskim |
| pubmed-article:3169114 | lifeskim:mentions | umls-concept:C0205171 | lld:lifeskim |
| pubmed-article:3169114 | lifeskim:mentions | umls-concept:C0205191 | lld:lifeskim |
| pubmed-article:3169114 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:3169114 | pubmed:dateCreated | 1988-10-31 | lld:pubmed |
| pubmed-article:3169114 | pubmed:abstractText | Flutamide is a nonsteroidal antiandrogen used in the treatment of prostatic carcinoma. We have investigated the disposition of flutamide and its two major metabolites in ten urological in-patients without significant liver or renal disease. After oral administration flutamide is absorbed from the gastrointestinal tract with a tmax of about 2 h. Flutamide undergoes extensive first-pass metabolism, and its major metabolites are 2-hydroxyflutamide and the hydrolysis product 3-trifluoromethyl-4-nitroaniline. After the oral administration of a single dose of 250 mg or 500 mg maximum flutamide plasma concentrations of 0.02 and 0.1 micrograms.ml-1 respectively were observed. Maximum plasma concentrations of 2-hydroxyflutamide for the same flutamide doses were 1.3 and 2.4 micrograms.ml-1 (mean of n = 2 or n = 3). Steady-state concentrations of the biologically active metabolite 2-hydroxyflutamide (0.94 +/- 0.23 micrograms.ml-1, mean +/- SD, n = 5) were found at 2-4 days after the administration of 250 mg every 8 h. The area under the plasma concentration time curve for 2-hydroxyflutamide averaged 11.4 (10.6 and 12.1) and 24.3 (21.5-29.4, n = 3) micrograms.ml-1.h for 250 mg and 500 mg flutamide orally. 2-Hydroxyflutamide and 3-trifluoromethyl-4-nitroaniline were eliminated monoexponentially with half-times of 4.3-21.9 and 4.3-17.2 h (n = 5) respectively. | lld:pubmed |
| pubmed-article:3169114 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3169114 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3169114 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3169114 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3169114 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3169114 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3169114 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3169114 | pubmed:issn | 0031-6970 | lld:pubmed |
| pubmed-article:3169114 | pubmed:author | pubmed-author:SchmoldtAA | lld:pubmed |
| pubmed-article:3169114 | pubmed:author | pubmed-author:BeckerHH | lld:pubmed |
| pubmed-article:3169114 | pubmed:author | pubmed-author:SchulzMM | lld:pubmed |
| pubmed-article:3169114 | pubmed:author | pubmed-author:DonnFF | lld:pubmed |
| pubmed-article:3169114 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3169114 | pubmed:volume | 34 | lld:pubmed |
| pubmed-article:3169114 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3169114 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3169114 | pubmed:pagination | 633-6 | lld:pubmed |
| pubmed-article:3169114 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:3169114 | pubmed:meshHeading | pubmed-meshheading:3169114-... | lld:pubmed |
| pubmed-article:3169114 | pubmed:meshHeading | pubmed-meshheading:3169114-... | lld:pubmed |
| pubmed-article:3169114 | pubmed:meshHeading | pubmed-meshheading:3169114-... | lld:pubmed |
| pubmed-article:3169114 | pubmed:meshHeading | pubmed-meshheading:3169114-... | lld:pubmed |
| pubmed-article:3169114 | pubmed:meshHeading | pubmed-meshheading:3169114-... | lld:pubmed |
| pubmed-article:3169114 | pubmed:meshHeading | pubmed-meshheading:3169114-... | lld:pubmed |
| pubmed-article:3169114 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:3169114 | pubmed:articleTitle | The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment. | lld:pubmed |
| pubmed-article:3169114 | pubmed:affiliation | Institute of Legal Medicine, University of Hamburg, Federal Republic of Germany. | lld:pubmed |
| pubmed-article:3169114 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3169114 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3169114 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3169114 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3169114 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3169114 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3169114 | lld:pubmed |
